Small Business Early Stage Investment

As an exclusive members-only benefit, BIO offers complimentary One-on-One meeting rooms during the JP Morgan Healthcare Conference, taking place January 7-10, 2013, in San Francisco.

Bioscience economic development in a nation as large and diverse as the United States is as varied as the country itself.  A complex array of factors influence the allocation of resources and the nature of bioscience industry development.

Dr. Cohen discusses the plight of today’s emerging biotech companies, and how the federal government can best support innovation within the industry.

State governments in 2011 continued to see regional economic growth in the life sciences industry and in 2012 will increasingly focus attention on technology transfer and venture funding as mechanisms to increase private sector innovation related activities within their jurisdictions. Realizing that entrepreneurship is a key ingredient in economic development, states and localities are undertaking the support of programs that assist high technology businesses, and that capitalize on state regional presence of universities and federal laboratories.

New Orleans shows the signs of a city reborn from the destruction brought on by Hurricane Katrina.  The changes in the city’s infrastructure and building projects have certainly been among them.  The city reached a  milestone its renaissance when the New Orleans BioInnovation Center (NOBIC) opened for business.

There are many reasons to be excited about financing early stage biotech companies. The BIO Investor Forum will assemble the most promising among promising discovery stage companies. 

In this global economy, nearly every competitor has access to big breakthroughs in technology and to the equipment and capital to produce standardized products, but those regions that possess the human capital, with its insights, competencies, and experience will have the competitive advantage.

Pete Pellerito discusses what is being done to provide the workforce for this broad and growing industry.

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.

BIOtechNOW’s Tracy Cooley talks to Dr. Schubert of the  Bioscience Association of West Virginia about biotech in West Virginia – major areas of growth, the outlook for growth of the industry within the states, and plans for the upcoming  BIO International Convention.

Emerging biotech companies with promising scientific innovation need a policy environment that will enable them to continue critical research and development of medical advancements and breakthroughs.

Current rules resulting from a 2003 Office of Hearings and Appeals decision have inhibited and interfered with the growth and survival of small private biotechnology companies and the development of promising technologies and products

The Massachusetts Life Sciences Center, which is tasked with administering the $1 billion state's life sciences initiative, has awarded five loans to start up companies, totaling $3.75 million.

Budget victories will help biotechnology in the Commonwealth

September 13 2011
These written comments were submitted to accompany the testimony of BIO's Interim Vice President for State Government Relations Pete Pellerito in support of legislative and regulatory environments that benefit biosciences industry job growth.
April 7 2011
The House Subcommittee on Healthcare and Technology held a hearing on The Creating Jobs Through Small Business Innovation Act of 2011, a bill that would reauthorize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which help fund small innovative companies on the brink of new technologies and discoveries.
March 24 2011
BIO submitted letters of support for the American Research and Competitiveness Act of 2011 (HR 942) to the lead House of Representatives sponsors.
November 1 2009
BIO is submitting this letter in response to the request by the United States Trade Representative (USTR) for comments to compile the National Trade Estimate (NTE) Report on Foreign Trade Barriers.
November 15 2008
BIO urges that changes to FIN46(R) accurately reflect the underlying economics of collaborations.
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
January 23 2014
BIO announced plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 16th annual BIO CEO & Investor Conference.
November 13 2013
The Bill will spur capital formation for small public companies
September 30 2013
NSF-funded companies focused on drug discovery, diagnostics and other platform technologies.
September 11 2013
Speakers will provide fresh insight, investment opportunities in biotech sector.